前沿生物(688221.SH):注射用艾博韋泰新納入國家醫保目錄
格隆匯12月28日丨前沿生物(688221.SH)公佈,根據國家醫保局、人力資源社會保障部關於《國家基本醫療保險、工傷保險和生育保險藥品目錄(2020年)》的通知,公司獨家專利產品注射用艾博韋泰(商品名:艾可寧®)新納入國家醫保目錄。
艾博韋泰是公司自主研發的國家一類新藥,於2018年5月獲得國家藥監局頒發的新藥證書,2018年10月,艾博韋泰被納入由中華醫學會感染病學分會、中國疾病預防控制中心頒佈的《中國艾滋病診療指南(2018版)》,艾博韋泰被列示為國內現有主要抗逆轉錄病毒藥物之一。艾博韋泰需與其他抗逆轉錄病毒藥物聯合使用,對主要流行的HIV-1病毒以及耐藥病毒均有效,通過注射方式每週給藥一次,具有用藥頻率低、起效快、耐藥屏障高、安全性高、副作用小等特點,為HIV合併症患者、肝腎功能異常患者、住院及重症患者等提供了新的用藥選擇,具有一定的臨牀不可替代性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.